Michael Morris, MD
Medical Oncology · New York, NYNPI 1255302055
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.8%. 2025 is the largest year on record at $26,093, 8.7 times the $3,011 reported in 2019.
Across 125 payments — averaging $796.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$17K
- Pfizer$17K
- Blue Earth Diagnostics$11K
- AbbVie$8K
- Daiichi Sankyo Inc.$8K
- Amgen$6K
- plus $34K from 16 others
Across 235 payments — averaging $129,173 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$26.2M
- Janssen Research & Development, LLC$2M
- Bristol Myers Squibb$1.2M
- Corcept Therapeutics$312K
- Progenics Pharmaceuticals, Inc.$201K
- F. Hoffmann-la Roche AG$199K
- plus $280K from 6 others
What the payments were for
- Consulting fees$58,33559%
- Speaking & faculty fees$26,99727%
- Grants$3,0003%
- Travel & lodging$7,0857%
- Food & beverage$4,1564%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 14 | $16,732 |
| Pfizer | 8 | $16,601 |
| Blue Earth Diagnostics | 5 | $10,500 |
| AbbVie | 13 | $7,958 |
| Daiichi Sankyo Inc. | 7 | $7,762 |
| Amgen | 12 | $6,483 |
| Progenics Pharmaceuticals, Inc. | 10 | $5,925 |
| Lantheus Medical Imaging, Inc. | 3 | $5,028 |
| Exelixis Inc. | 3 | $3,989 |
| Advanced Accelerator Applications | 3 | $3,347 |
| Janssen Research & Development, LLC | 6 | $2,955 |
| Telix Pharmaceuticals | 4 | $2,803 |
| Curium US LLC | 2 | $2,713 |
| AstraZeneca | 16 | $2,458 |
| GSK | 1 | $2,400 |
| Janssen Global Services, LLC | 5 | $653 |
| Johnson & Johnson | 5 | $489 |
| Bayer | 3 | $291 |
| Sanofi | 2 | $287 |
| Novartis | 1 | $135 |
| Roche Products Limited | 1 | $53 |
| Myovant Sciences Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUCCIX$5,606
- Axumin$4,000
- Cabometyx$3,960
- PYLARIFY$3,265
- Lutathera$3,000
- 64Cu-PSMA-I&T$2,700
- 177Lu-PSMA-I&T$2,700
- TALZENNA$2,187
- LYNPARZA$1,028
- Erleada$502
- NO PRODUCT DISCUSSED$287
- Xofigo$274
- Balversa$116
- ORGOVYX$107
- XTANDI$107
How this compares
$99,573 in reported general payments places this provider in the 85th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 120 | $1,527,899 |
| XtandiEnzalutamide | 87 | $1,215,017 |
| ErleadaApalutamide | 22 | $358,399 |
| OrgovyxRelugolix | 65 | $169,660 |
| ZytigaAbiraterone Acetate | 12 | $124,076 |
| Abiraterone Acetate | 72 | $104,434 |
| Prednisone | 98 | $452 |
| Alendronate Sodium | 16 | $59 |
| Tamsulosin Hcl | 13 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $291 | $1,527,899120 claims |
| Johnson & JohnsonErleada, Zytiga | $489 | $482,47534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 498 medical oncology providers in New York.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.